


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.32%
-0.01%
-13.15%
+0.64%
-0.89%
JNJ
Johnson & Johnson
$206.91
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive

Outperform the market
JNJ Price Performance
$205.33 (+0.77%)
$188.16 (+9.96%)
$173.33 (+19.37%)
$147.77 (+40.02%)
JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

JNJ overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Investors confidence is positive

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
NBTX
21.67
-3.65%
BLTE
160.82
-2.70%
ANNX
5.04
+0.80%
SNDX
20.74
-1.57%
REGN
773.94
-0.84%
What is JNJ current stock price?
What are JNJ stock strengths?
What is JNJ Risk Level?
What is JNJ market cap and volume?
What is JNJ current Stock IQ?
Should I buy JNJ stock right now?
Is JNJ a Strong Buy right now?
What does a 'Strong Buy' rating mean for JNJ?
What does a 'Strong Sell' rating mean for JNJ?
What factors influence JNJ's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.32%
-0.01%
-13.15%
+0.64%
-0.89%
JNJ
Johnson & Johnson
Current Price
$206.91
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive

Outperform the market
Linked to JNJ
NBTX
21.67
-3.65%
BLTE
160.82
-2.70%
ANNX
5.04
+0.80%
SNDX
20.74
-1.57%
REGN
773.94
-0.84%

JNJ Price Performance
$205.33 (+0.77%)
$188.16 (+9.96%)
$173.33 (+19.37%)
$147.77 (+40.02%)
JNJ Analysts Opinion
JNJ Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Investors confidence is positive

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

Average key support and resistance price levels
JNJ Stock IQ
JNJ Latest Analysis
Johnson & Johnson (JNJ) Ends Mid-Stage Eczema Study After Missing Efficacy Bar. Johnson &. Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26 Johnson &. Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with moderate to severe atopic dermatitis. The decision followed an interim analysis showing the treatment did not meet its [….]
Tue Dec 30, 2025
DYNF PLTR BAC JNJ: ETF Inflow Alert. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares United States Equity Factor Rotation Active ETF (Symbol: DYNF) where we have detected an approximate $200.2 million dollar inflow -- thats a 0.6% inc
Mon Dec 29, 2025
Johnson & Johnson halts mid-stage trial of experimental eczema drug. Johnson & Johnson said it discontinued a mid-stage study of its experimental drug to treat atopic dermatitis after it failed to meet efficacy goals.
Fri Dec 26, 2025
Can J&Js Pipeline Progress in 2025 Aid Long-Term Growth?. JNJs rapidly advancing pipeline new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
Fri Dec 26, 2025
Heres Why Johnson & Johnson (JNJ) Surged in Q3. Meridian Funds managed by ArrowMark Partners released its Meridian Hedged Equity Fund third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter the market is more focused on the tailwind of policy easing than the headwind of weakening fundamentals resulting in substantial gains despite stagflation emerging as a key concern. [….]
Wed Dec 24, 2025
Johnson & Johnsons Options: A Look at What the Big Money is Thinking. Whales with a lot of money to spend have taken a noticeably ish stance on Looking at options history for Johnson &. Johnson (NYSE:) we detected 11 trades.If we consider the specifics of each trade it is accurate to state that 72% of the investors opened trades with ish expectations and 0% with bearish.From the overall spotted trades 4 are puts for a total amount of $411540 and 7 calls for a total amount of $424038.Analyzing
Wed Dec 24, 2025
Heres Why Johnson & Johnson (JNJ) Surged in Q3.
Wed Dec 24, 2025
5 Big Drug Stocks That May Continue to Outperform in 2026. Five big drugmakers including LLY and JNJ are riding innovation dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Tue Dec 23, 2025
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised). JNJ wins FDA approval for a subcutaneous version of Rybrevant cutting treatment time to minutes and boosting convenience across NSCLC indications.
Tue Dec 23, 2025
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play . J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution new drugs and pipeline progress support ish momentum.
Mon Dec 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.